€107.40 ABVX.PA stock pre-market: earnings due Mar 23 may reset targets

We see ABVX.PA stock trading at €107.40 in pre-market trade on 19 Mar 2026, ahead of an earnings report due 23 Mar 2026. Traders will watch revenue and clinical updates for ABIVAX SA as the company remains a biotech growth story. Volatility is likely; the stock is off -2.01% today and faces mixed analyst targets and model forecasts.

ABVX.PA stock: pre-market price and immediate drivers

ABIVAX SA (ABVX.PA) opened at €111.00 and trades near €107.40 in pre-market on EURONEXT. The intraday range is €106.40–€111.00 and volume shows 93,824.00 shares so far. Investors are pricing an upcoming earnings announcement on 23 Mar 2026, plus new clinical readouts for obefazimod, as the primary short-term catalysts.

Earnings preview and what to watch in the ABVX.PA earnings report

Earnings on 23 Mar 2026 should clarify cash burn and R&D progress. ABIVAX posts negative earnings; trailing EPS is -4.44 and TTM PE is -24.19. We will watch operating cash flow, guidance on trial timelines, and any licence or partnership updates that could change valuation quickly.

Analyst targets and market consensus for ABVX.PA stock

Sell-side coverage is skewed bullish. MarketBeat shows a consensus price target of €136.69 and multiple buy ratings. That consensus implies a +27.29% upside from €107.40. Still, opinions vary: individual targets range higher and lower, so earnings will likely reshape those estimates MarketBeat and technical momentum.

Meyka AI grades, technicals and valuation signals

Meyka AI rates ABVX.PA with a score of 74.45 out of 100 — Grade B+ (BUY). This grade factors in S&P 500 and sector comparison, industry metrics, financial growth, key ratios, forecasts, and analyst consensus. Technicals show RSI 56.42, MACD histogram 0.99, and 50‑day average €102.02 versus 200‑day €75.88, which supports a bullish trend but elevated valuation ratios remain a concern.

Meyka AI’s forecast model and price scenarios

Meyka AI’s forecast model projects short and medium term figures. Monthly model: €100.11 (implied -6.79% versus current). Quarterly: €79.44 (implied -26.03%). Yearly: €51.19 (implied -52.36%). Forecasts are model-based projections, not guarantees, and assume current clinical and funding paths.

Sector context and liquidity risks for ABVX.PA stock

ABIVAX trades in the European Healthcare sector, which is down -1.05% today. The stock’s market cap is €8,492,400,247.00 and shares outstanding are 79,072,628.00. Average daily volume is 153,170.00, so liquidity is adequate for institutional flows but headline-driven moves can widen spreads rapidly.

Final Thoughts

Key takeaways for ABVX.PA stock ahead of the 23 Mar 2026 earnings release: first, the pre-market price €107.40 already reflects strong clinical interest and a crowded bullish analyst view. Market consensus target €136.69 implies +27.29% upside, while Meyka AI’s one‑year forecast of €51.19 implies a -52.36% downside. Second, fundamentals show heavy R&D spend and negative EPS -4.44, so any positive cash guidance or trial news could validate higher targets. Third, our B+ grade reflects sector outperformance potential balanced against stretched valuation metrics and execution risk. We recommend watching earnings metrics closely and sizing positions for volatility. All grades and forecasts are model outputs, not guarantees. Meyka AI provides this as an AI-powered market analysis platform to help frame the risk-reward ahead of earnings.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.